

December 15, 2023

The BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 541540

Scrip Code: SOLARA

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) – Change in the Senior Management.

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform the following change in the Senior Management Team of the Company.

1. Dr. Sudhir Nambiar has tendered his resignation from the position of Chief Scientific Officer (CSO). The resignation letter is enclosed herewith as Annexure A. As a result, he will cease to be Chief Scientific Officer (CSO) with effect from the close of business hours on December 22, 2023.
2. Dr. Hero Velladurai has been appointed as Chief Scientific Officer (CSO) with effect from December 15, 2023

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 is given in Annexure 'B' attached to this letter.

We request you to take the same on record.

Thanking you,
Yours faithfully,

For Solara Active Pharma Sciences Limited

S. Murali Krishna
Company Secretary

Encl.: As above.

Annexure A

15th Dec 2023

To,

The MD & CEO
Solara Active Pharma Sciences,

Sub: Resignation from the post of Chief Scientific Officer

Dear Poorvank,

I am resigning from the position of CSO for Solara Active Pharma effective today ie 15th December 2023. As discussed, my last working day will be 22nd December 2023.

Thank you for the support during my tenure in the company.

Sincerely,



Dr. Sudhir Nambiar
Chief Scientific Officer

ANNEXURE B

Particular	Information of such event	
Name	Dr. Sudhir Nambiar	Dr. Hero Velladurai
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Resignation	Appointment
Date of appointment/reappointment/cessation (as applicable) & term of appointment/re-appointment	Resignation of Dr. Sudhir Nambiar as Chief Scientific Officer (CSO) with effect from the close of business hours on December 22, 2023.	Appointment of Dr. Hero Velladurai as Chief Scientific Officer (CSO) with effect from December 15, 2023.
Brief profile (in case of appointment)	Not applicable	<p>Dr. Hero Velladurai Joins us as Chief Scientific Officer API R&D with 27 years of rich experience in Pharmaceutical Industry. His last assignment was with Caplin Point Laboratory, API Research and Development Centre as ‘President’.</p> <p>In his long R&D career, Dr. Hero has directly contributed to development & commercialization of more than 50 API’s in pharmaceutical industries which includes Cephalosporin drugs, Penicillin drugs, Carbapenem drugs, Iron Complexes (Oral and Injectables), Cross-linked polymers, Oncology drugs, Antiretroviral HIV Drugs, Antidiabetic drugs, Anticoagulant drugs, Antihypertensive drugs, Anti-psychotic drugs, Antidepressant drugs and Anti-cholesterol drugs, non-depolarising neuromuscular blocking agents etc.</p> <p>In his earlier assignments, Dr Hero was associated with Aurobindo Pharma, Navinta LLC, Orchid Chemicals & Pharmaceuticals Ltd and completed his Ph.D., from University of Madras, Chennai.</p>